The Mechanism Of Action Of EGFR In Cancer Development And Targeted Therapy And Its Optimization Strategy

Abstract

The incidence of cancer has continued to rise, particularly among the elderly population with mortality rates surpassing those of other diseases, drawing significant societal attention. The causes of cancer are complex with approximately 5% linked to genetic factors, while studies on the correlation between histone modifications and mutation rates reveal potential differences in germline and somatic cells. The EGFR a receptor tyrosine kinase on the cell membrane is closely associated with the development of various cancers such as non-small cell lung cancer and colorectal cancer, due to its overexpression or mutations. Although significant progress in EGFR targeted therapy, compound mutations and drug resistance still need improvement. This study examined the relationship between EGFR and cancer, using EGFR as a targeted therapy for cancer, including monoclonal antibodies (mAbs) (cetuximab) and combination therapy (pertuzumab). These findings make EGFR targeted therapy important in inhibiting tumor growth and reducing the incidence rate of cancer. In addition, the study also discussed the different populations and their impact on treatment strategies. This study provides a theoretical basis for optimizing EGFR targeted therapy. The research will further investigate the mechanisms of drug resistance and new combination therapies to improve the accuracy and efficacy of cancer treatment.